Clarion News

Perspectives from the 2019 AACR Annual Meeting


Clarion joined over 20,000 attendees who gathered in Atlanta for the 2019 American Association for Cancer Research Annual Meeting to learn about cutting-edge advances in cancer biology and translational medicine. Below we summarize selected highlights of progress in immunotherapy, I-O biomarkers, cell therapy, targeted therapy, and new technologies that may enhance research and development in oncology.

Key takeaways

Immuno-oncology continues to make exciting progress, including:

  • New immunotherapy drugs and drug combinations—including unprecedented early efficacy for pancreatic cancer and glioblastoma
  • Exploratory I-O biomarkers and biomarker combinations
  • Innovations in engineered cell therapy—including the most promising efficacy to date for solid-tumor CAR-T cell therapy

Targeted therapy advances include:

  • Novel treatments to address acquired resistance
  • Novel mechanisms for hard-to-treat cancers

Enabling technologies that may accelerate new product development include:

  • New preclinical models for testing immunotherapy regimens
    New digital systems for improving patient care and translational/clinical research

Click here to read the full perspectives for the 2019 AACR Annual Meeting

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.